Cambridge Healthtech Institute’s 5th Annual
Feasibility, Site Selection and Study Activation
Analytics-Driven Trial Design and Execution for Site-Centered and Hybrid Trials
3-4 October 2022
We are pleased to announce production of Cambridge Healthtech Institute’s Feasibility, Site Selection, and Study Activation: Analytics-Driven Trial Design and Execution for Site-Centered and Hybrid Trials being held 3-4 October 2022, at
the
InterContinental Barcelona-Fira Center in Barcelona, Spain. SCOPE Europe will be a hybrid conference in 2022 serving both in-person and virtual attendees.
Early development planning, feasibility assessment, protocol development, and site selection are arguably the most critical components of the clinical trial process. Performing these first steps effectively will significantly impact the likelihood of
completing the trial on time and within budget. Innovative data and analytics capabilities, new protocol development and feasibility assessment processes, and novel approaches to stakeholder communication and collaboration are improving clinical trial
timelines and outcomes and driving trial success. The gathering will be part of the Summit for Clinical Trials Operations Executives (SCOPE) Europe, a two-day event made up of shared plenary keynotes from biopharma thought leaders, four conference
tracks focused on specific issues and functions within the clin ops, innovation and research enterprise, informal and interactive breakout discussion groups, and networking. Please see the overall program map below for 2022. Topics to be discussed
at the Feasibility, Site Selection and Study Activation conference track include:
- The impact of COVID on feasibility and site management
- Planning and deploying hybrid trials by developing truly patient-centric protocols that enable patient choice
- Best practices in protocol design to reduce amendments and improve trial success
- Connecting stakeholders and internal champions across functions and silos during early clinical development planning, program design, and development of the Target Product Profile (TPP)
- Data science in protocol optimization
- Incorporating site and patient input into the protocol development process
- Building and implementing a data-driven site selection approach
- New technologies and AI-enabled solutions in clinical trial feasibility and site selection
- Protocol feasibility and clinical trial simulation
- Tools and strategies to improve site activation and study start-up in both decentralized/remote and site-centered trials
If you are interested in presenting, please submit a speaking proposal for review.
We are looking for actual implementation stories and lessons learned, not theoretical talks. Co-presentations featuring speakers from different departments involved in the project are encouraged.
Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators, and those from academic/hospital centers. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Micah Lieberman
Executive Director, Conferences
Cambridge Healthtech Institute (CHI)
Phone: (+1) 541.482.4709
Email: mlieberman@healthtech.com
For partnering and sponsorship information, please contact:
Companies A-K:
Ilana Quigley
Sr. Manager, Business Development
Cambridge Healthtech Institute (CHI)
Phone: (+1) 781.972.5457
Email: iquigley@healthtech.com
Companies L-Z:
Patty Rose
Sr. Manager, Business Development
Cambridge Healthtech Institute (CHI)
Phone: (+1) 781.972.1349
Email: prose@healthtech.com
For media and association partnerships, please contact:
Rich Handy
Senior Director, Marketing
Cambridge Healthtech Institute (CHI)
Phone: (+1) 781.972.5456
Email: rhandy@healthtech.com